We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

SAN DIEGO — SAN DIEGO — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $59.2 million in its fourth quarter. The San Diego-based company said it had a loss of 9 cents per share. Losses, adjusted ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...

Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

ImmunityBio (IBRX) delivered earnings and revenue surprises of 42.31% and 13.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...

In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against the other stocks. The stock market kicked off the trading week in a bloodbath, erasing last week ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) traded up 6.8% on Tuesday following a better than expected earnings announcement. The stock traded as high as $3.01 and last traded at $3.05.